Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	133.82	115.85	118.37	234.2	118.72
Short-Term Investments	9	480.22	217.63	128.6	622.2
Cash & Short-Term Investments	142.82	596.07	336	362.79	740.92
Cash Growth	-76.04%	77.40%	-7.38%	-51.03%	101.33%
Accounts Receivable	439.66	308.46	234.21	231.07	90.98
Other Receivables	1.61	-	-	-	-
Receivables	441.27	308.46	234.21	231.07	90.98
Inventory	176.48	141.86	127.6	100.12	53.91
Prepaid Expenses	64.64	38.95	48.61	45.02	40.48
Total Current Assets	825.21	1,085	746.42	739.01	926.29
Property, Plant & Equipment	82.14	75.04	74.94	75.57	8.79
Goodwill	580.36	416.82	416.82	409.05	-
Other Intangible Assets	981.47	401.83	472.88	546.65	-
Long-Term Deferred Tax Assets	-	3.86	4.39	44.43	155.43
Other Long-Term Assets	56.15	80.6	17.82	26.8	13.91
Total Assets	2,525	2,063	1,733	1,842	1,104
Accounts Payable	20.9	10.25	11.82	17.69	1.54
Accrued Expenses	144.92	128.85	100.68	97.66	22.17
Current Portion of Long-Term Debt	-	-	-	13.33	89.42
Current Portion of Leases	11.28	-	-	2.1	2.28
Current Unearned Revenue	-	-	-	-	1.75
Total Current Liabilities	177.09	139.1	112.49	130.79	117.15
Long-Term Debt	2,143	1,506	1,499	1,493	787.26
Long-Term Leases	23.29	-	32.2	32.69	0.54
Long-Term Unearned Revenue	-	-	-	-	2.53
Long-Term Deferred Tax Liabilities	42.92	-	-	-	-
Other Long-Term Liabilities	90.57	54.76	5.52	15.47	-
Total Liabilities	2,477	1,700	1,649	1,672	907.48
Common Stock	0.12	0.12	0.13	0.14	0.14
Additional Paid-In Capital	12	-	2.41	27.37	256.35
Retained Earnings	54.79	359.87	90.55	143.22	-58.91
Comprehensive Income & Other	-18.09	3.83	-9.28	-0.92	-0.62
Shareholders' Equity	48.81	363.82	83.81	169.8	196.95
Total Liabilities & Equity	2,525	2,063	1,733	1,842	1,104
Total Debt	2,177	1,506	1,531	1,541	879.49
Net Cash (Debt)	-2,034	-909.72	-1,195	-1,178	-138.57
Net Cash Per Share	-16.42	-7.03	-8.91	-8.38	-0.94
Filing Date Shares Outstanding	118.02	123.15	126.82	135.37	137.7
Total Common Shares Outstanding	117.78	123.14	126.77	135.15	137.5
Working Capital	648.12	946.24	633.93	608.22	809.14
Book Value Per Share	0.41	2.95	0.66	1.26	1.43
Tangible Book Value	-1,513	-454.83	-805.89	-785.9	196.95
Tangible Book Value Per Share	-12.85	-3.69	-6.36	-5.81	1.43
Machinery	68.2	57.53	50.78	43.13	18.26
Leasehold Improvements	7.52	7.01	6.99	6.73	1.63
Order Backlog	289.5	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.